INTRODUCTION {#sec1-1}
============

Raised total cholesterol level is a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. Globally, a third of ischemic heart diseases are attributable to high cholesterol. 10% reduction in serum cholesterol in men aged 40 has been reported to result in a 50% reduction in heart diseases within 5 years.\[[@ref1]\] In view of limitations of conventional drugs researches on herbal drugs are on the increase. *Guggulu* is such a drug which has got attention due to its various properties such as hypocholestremic,\[[@ref2]\] lipid lowering,\[[@ref3][@ref4]\] anti-arthritic,\[[@ref5]\] anti-inflammatory,\[[@ref6][@ref7][@ref8][@ref9]\] anti oxidant,\[[@ref10]\] cardio protective,\[[@ref11]\] antimicrobial\[[@ref12]\] etc. There have been a number of studies that have evaluated anti-hyperlipidaemic activity of *Guggulu*.\[[@ref13][@ref14][@ref15][@ref16]\]

*Guggulu* was first introduced to the scientific world in 1966 as a lipid lowering drug\[[@ref3]\] and soon after, the interest in using *Guggulu* as a remedy for treating or preventing hypercholesterolemia and related cardiovascular diseases became wide spread in the Western world.\[[@ref17]\]

Ayurveda considers fresh *Guggulu* for *bṅhmaṇa* (body mass increasing) effect; while *lekhana* (scarificant) effect is attributed to the old one.\[[@ref18]\] This signifies that therapeutic utilities of new and old *Guggulu* are different possibly due to certain changes which occur with time. Though studies are reported on *Guggulu*, comparative efficacy of *navīna* (fresh) and *purāṇa* (old) samples are not reported till date. Considering this, we attempt to evaluate the comparative effect of fresh and old *Guggulu* in Hyperlipidaemia.

MATERIALS AND METHODS {#sec1-2}
=====================

Drug {#sec2-1}
----

*Guggulu* wildly cultivated at Dwaraka Forest Range, Gujarat was collected from Gujarat State Forest Development Corp. Ltd., Vadodara during February 2011 (Batch no. B 05, code-148600). This sample was preserved in polyethylene bags at room temperature (28-32°C) to make it old. Though specific time period is not mentioned for *Guggulu* to turn old; the sample was stored for one year considering general terminology.\[[@ref19]\] Another sample of fresh Guggulu was collected in the same manner in February 2012 (Batch no. B 01, code-128500). Both the samples were purified following classical method.\[[@ref20]\]

Selection of patients {#sec2-2}
---------------------

The study was conducted at Jamnagar. The study was started after obtaining approval from the Institutional Ethics Committee (PGT/7-A/Ethics/2011-2012/2087/26, dated-05/09/2010) and registered at Clinical Trial Registry of India, ICMR, New Delhi. (CTRI/2011/11/002117).

### Inclusion criteria {#sec3-1}

Patients of either sex aged 20 to 60 years with *svedādhikya* (excessive sweating), *daurbalya* (generalized weakness), *śvāsakaṣṭatā* (breathlessness), *nidrādhikya* (excessive sleep), *atikṣudhā* (excessive eating), *aṅgagaurava* (heaviness in body), *gātrāsāda* (fatigue), *aṃgaśaithilya* (flabbiness)\[[@ref21]\] and increased levels of any of the serum lipids such as S. cholesterol (\>200 mg/dL), S. triglycerides (\>150 mg/dL), S.LDL (\>130 mg/dL), S. VLDL (\>40 mg/dL)\[[@ref22]\] were included in the study.

### Exclusion criteria {#sec3-2}

Obese patients associated with hypothyroidism, hypertension, Diabetes Mellitus, Cushing\'s syndrome and other concomitant serious disorders involving liver, kidneys, heart, lungs and other organs, gravid women and lactating mothers were also excluded from the study.

Posology {#sec2-3}
--------

Patients were randomly grouped into two. Patients of Group A were administrated with *śuddhanavīna* (fresh) *Guggulu* (NG) and those in Group B were administered *śuddhapurāṇa* (old) *Guggulu* (PG). One gram of the drug with luke warm water before food was administered twice a day in both the groups for eight wks. Follow-up was done for two weeks post treatment. Patients were advised to avoid excess fatty diet such as fried spicy substances, bakery items, fast foods, cold drinks, ice creams, chocolates etc., They were also advised to not sleep during the day and to do physical exercise.

Laboratory investigations {#sec2-4}
-------------------------

Routine haematological tests such as TLC, RBC, Hb, WBC, ESR and urine examinations were carried out in all patients to assess the condition of disease and to exclude any underlying pathology. Biochemical investigations such aslipid profile, blood urea, RBS, S. creatinine, SGOT, SGPT, alkaline phosphatase etc., were carried out.

Assessment criteria {#sec2-5}
-------------------

Classical signs and symptoms of *Medoroga* were taken as subjective criteria. Multidimensional scoring pattern \[[Table 1](#T1){ref-type="table"}\] was adopted to give results objectively and for statistical analysis. This score was obtained before and after the treatment and percent relief was determined to assess the efficacy of therapy. Objective criteria were assessed on the basis of body weight, BMI and biochemical investigations done before and after treatment in terms of percentage relief. Girth measurements of certain regions were also noted as below:\[[@ref23]\]

###### 

The details of the score adopted for the main signs and symptoms

![](ASL-35-101-g001)

Neck - Between the neck below the level of thyroid cartilageChest - In normal expansion at the level of nippleAbdomen - At the level of umbilicusHip - At the level of highest point of distension of buttockMid-thigh - Mid of the thigh between pelvic and knee jointsMid arm - Mid of the arm between shoulder joint and elbow joint.

Results and interpretation {#sec2-6}
--------------------------

Overall effect of therapy on each scale was calculated with reference to percentage improvement in all symptoms, the relief was assessed on the below criteria:

\<25% - Poor response26--50% - Mild improvement51--75% - Moderate improvement76--99% - Marked improvement100% - Complete remission.

Statistical analysis {#sec2-7}
--------------------

The data was expressed as mean ± standard error of mean for both groups. Student\'s *t*-test was used to compare the data to determine significance between groups at *P* \< 0.05.

OBSERVATIONS AND RESULTS {#sec1-3}
========================

The study was carried out in 72 registered patients of *medoroga*, out of which 13 patients dropped out and 59 completed the prescribed course of treatment. 5 patients experienced inconvenience due to the smell of the medicine, five migrated to some other place while three patients experienced excessive menstruation during treatment. In group A, 30 patients were administrated with NG whereas group B comprised of 29 patients who were administered PG.

Summary of chief complaints is recorded in [Table 2](#T2){ref-type="table"}. Highly significant (P \< 0.001) decreases was found in *ālasya* (laziness), *kṣudraśvāsa* (dyspnea), *daurbalya* (weakness), *aṃgagaurava* (heaviness in body), *gātrāsāda* (fatigue) and *aṅgaśaithilya* (flabbiness in body) in both groups. But NG group showed highly significant (*P* \< 0.001) result in *ālasya*, *daurbalya*, *gātrāsāda* and *aṅgaśaithilya*; whereas in *kṣudraśvāsa*, and *aṃgagaurava*, PG group found more relief than the NG group.

###### 

Effect of both groups in cardinal symptoms of *Medoroga*

![](ASL-35-101-g002)

Result of lipid profile, body weight and BMI is placed in [Table 3](#T3){ref-type="table"}. Both groups showed non-significant decreases in S. cholesterol. NG treated group exhibited significant decrease in S. triglycerides level (17.7%) and VLDL (18.36%) while showing non-significant decreases in S.HDL. PG group also showed significant decreases in S. triglycerides level (13.64%) and VLDL (11.07%) while a non-significant increase was found in S. HDL. Both groups exhibited statistical non-significant (*P* \> 0.05) changes in LDL level. Administration of PG showed a statistically highly significant (*P* \< 0.001) decrease in body weight and BMI. Effect of both drugs on haematological and other biochemical parameters are shown in [Table 4](#T4){ref-type="table"}.

###### 

Effect of therapy on lipid profile, BMI and body weight

![](ASL-35-101-g003)

###### 

Effect of therapy in haematological and biochemical parameter

![](ASL-35-101-g004)

PG treated group showed significant reduction in circumferences of chest (1.89%), abdomen (1.6%), hip (1.52%) and mid thigh (3.49%); whereas the NG treated group reduced circumferences of mid arm (1.92%), chest (1.51%), hip (1.4%) and mid thighs (4.3%). All of these results were significant or highly significant and are tabulated in [Table 5](#T5){ref-type="table"}.

###### 

Effect of both trial drugs on girth measurement

![](ASL-35-101-g005)

Overall results are summarized in [Figure 1](#F1){ref-type="fig"}. One patient (3.44%) from PG group showed marked improvement. Two patients (6.66%) of NG group and six patients (20.68%) of PG group showed moderate improvement. Seventeen patients (56.67%) of NG group and twelve patients (41.37%) of PG group showed mild improvement. Improvement was found in eleven patients (36.67%) of NG group and ten patients (34.48%) of PG group.

![Overall effect of *Navīna Guggulu* (NG) and Purāṇa *Guggulu* (PG)](ASL-35-101-g006){#F1}

DISCUSSION {#sec1-4}
==========

In NG group, all closely related biochemical markers i.e. S. cholesterol, LDL, direct and indirect bilirubin, S. alkaline phosphatase have shown statistically non-significant decrease. The common site of synthesis, regulation and or excretion of these products is the liver. Simultaneously VLDL shows highly significant decrease. S. cholesterol is necessary for synthesis of all steroidal hormones. It is noted that plant sterols decrease absorption of cholesterol. Liver is responsible for 80% of endogenous cholesterol synthesis. The liver has a major role in controlling plasma levels of LDL cholesterol, because most of the LDL receptors are located in the liver.\[[@ref24]\] Liver synthesizes cholesterol and removes cholesterol from lipoprotein remnants, it also controls body cholesterol pool by converting cholesterol to bile acids. It is an established and published fact that, Guggulsterone enhances transcription of bile salt export pump.\[[@ref25]\] In the current study, the NG group shows decrease in many lipid parameters like S. cholesterol, S. LDL, S. VLDL as well as S. bilirubin and S. alkaline phosphatase. In this group, comparatively more quantity of Guggulostereone-E and Guggulsterone-Z have been found in HPLC study which supports the fact that plant sterols decreases absorption of cholesterol.\[[@ref26]\] In PG group, there was also a decrease in similar components of lipid profile but there wasn't a decrease in S. Bilirubin, SGPT and Alkaline Phosphatase. It may be considered that the above observations favours the theory of enhancement of transcription of bile salt export pump by Guggulsterone. Similar kind of results were also found in an animal experimental study.\[[@ref27]\]

NG group shows statistically non-significant increase in S. globuline. When albumin level is decreased, body tries to compensate it by increasing the production of globulins from reticulo-endothelial system.\[[@ref28]\] Blood is a part of reticulo-endothelial system. Red blood cells, platelets are basically reticulocytes which are produced and released from bone marrow.\[[@ref29]\] Thus non significant increase in packed cell volume (PCV), RBC, platelet supports stimulation of stem cell production from bone marrow leading to proliferation of these cells and red cell indices i.e. PCV.

NG group exhibits statistically significant decrease in blood sugar and statistically non-significant increase in S. creatinine after treatment. Liver and kidneys are the two organs that synthesize and secrete glucose into the blood stream for utilization by other organs. In the fasting state, glucose is released into the bloodstream by hepatic glycogenolysis and gluconeogenesis which is termed as hepatic glucose output. The kidney also produces glucose by gluconeogenesis. The process is facilitated by excess of glucagon and lowered insulin level.\[[@ref30]\] Supressibility of hepatic glucose output contributes significantly to both fasting as well as post prandial hyperglycemia. Restoration of inhibition of hepatic gluco neogenesis to normal is one among the goals of ideal initial therapeutic agent for diabetes. increased glomerular permeability causes albuminuria hence hypoalbuminemia, a similar condition was observed in this treatment group.

Statistically non-significant increase in SGPT may further support hepatic functional impairment along with decreased S. albumin and blood sugar. Although SGOT is found significantly decreased in NG group, still SGPT/SGOT ratio was found to be normal (\<2) and there is statistically non-significant increment in S. globulin but ratio of albumin/globulin is found to be normal (\<1.4). Hence, from these values, hepatic impairment cannot be established.

The group which received PG had shown statistically significant increment in total S. biliribin and statistically non-significant increment in direct bilirubin, SGPT, S. alkaline phosphatase but A:G ratio and SGPT: SGOT ratio was not crossing its normal limits - a similar finding as NG group. Hence, the changes are less likely due to hepatic impairment.

The possibility of hypolipidemic effect exclusively due to restriction of excessively fatty diet and recommendation of exercise, is excluded by evidence of significant alteration in biological markers of hepatic function (major site of lipid metabolism). Increased transformation of lipids into bile salts (compensatory change in hepatic function) is probably a significant cause for hypolipidemic effect of trial drugs as evidenced by elevation of SGPT, decrement in total bilirubin, direct bilirubin. Reduction in fasting plasma sugars (which is mainly dependent on hepatic glucose output) and S. albumin was also noted. This suggests that hypolipidemic action of both trial drugs is probably due to increased excretion through Liver.

Reduction in weight is also due to anti-obesity effect of *Guggulu*.\[[@ref31]\] *Gomūtra*, the media used for *śodhana* process, is a proven bio-enhancer.\[[@ref32]\] It may also enhance anti-obsesity activity. Suppression of appetite probably has major role in reduction of body weight by both drugs. This is because weight loss along with reduction in circumferences of body parts was found comparatively more in PG group along with comparatively greater reduction of *Kṣudhādhikya*. Alterations in biogenic amines anddopamine *ß*-hydroxylase activity may be one of the possible mechanisms for the anti-lipidaemiceffect of guggulsterone.\[[@ref33][@ref34]\] Hence it may be postulated that PG maybe working primarily by appetite suppression through change in hormones responsible for appetite.

Vitiated *kapha* and *vāta* are crucial in the manifestation of *Medoroga*. Hence, drugs that pacify *Vāta* and *Kapha* should be selected in treating the condition. As *Guggulu* is having all pharmacodynamic actions against the *kapha* and *medodhātu* such as *kaṭu-tikta rasa* (pungent-bittertaste); *laghu* (light), *tīkṣṇa* (\~sharpness), *sūkṣma* (\~subtle), *guṇa* (quality); *uṣṇa* (hot) *vīrya* and *kaṭu vipaka*,\[[@ref35]\] it enhances metabolic activity in the body, which digest the produced *āma*. *Gomūtra* is dominated by *kṣārīya* (alkaline) substances, *kaṭu-tikta rasa*, *tīkṣṇa* and *laghu guṇa*, *uṣṇa vīrya* and *kaṭu vipāka*.\[[@ref36]\] By virtue of these properties, it enhances *āma-medohara* action of *Guggulu* and reduces various lipid contents in the body. These elevated lipids can be inferred to be *āma medodhātu*. Old (*purāṇa*) *Guggulu* is attributed with *atilekhana* property which manifests as reduced body weight and BMI in treated patients, when compared to those treated with fresh (*navīna*) *Guggulu*. Both *Guggulu* and *Gomūtra* have the action of *kaphavātaśāmaka*. Due to synergistic effect, *Guggulu* processed in *Gomūtra* may enhance this action hence may be beneficial in reducing the symptoms of *Medoroga*. These qualities are also beneficial in lowering the lipid profile in the patients.

CONCLUSION {#sec1-5}
==========

Lipid lowering property and weight reducing effect of *Guggulu* gets altered with aging of *Guggulu*, in that, old *Guggulu* is comparatively better in the management of hyperlipidemia (*Medoroga*). The active principles behind this specific activity may be further evaluated through well designed experimental trials.
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